1. Scrip
  2. >>COVID-19

An Ambitious COVID-19 Vaccine Development Plan For Pfizer And BioNtech

 
• By Jessica Merrill

Pfizer said it is dosing patients now with an mRNA-based vaccine and expects human data in May/June, with a goal to have a vaccine available for emergency use possibly by October.

Doctor giving patient vaccine, flu or influenza shot or taking blood test with needle. Nurse with injection or syringe. Medicine, insulin or vaccination. Hospital office room.
Pfizer's COVID-19 vaccine is in human testing • Source: Shutterstock

Pfizer Inc. laid out an ambitious timeline to bring a COVID-19 vaccine to patients as early as the fall, potentially with an emergency use authorization. Worldwide R&D President Mikael Dolsten outlined the plan during the company's first quarter sales and earnings call on 28 April.

The company is developing a messenger RNA-based vaccine with BioNTech under a collaboration expanded in April to include an investigational COVID-19 vaccine. The two companies have already been partnered on a flu vaccine collaboration since 2018

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Atara Does An About Face As FDA Lifts Ebvallo Hold

 
• By Alaric DeArment

The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.